Can umbralisib bring PI3K delta out of the shadows?
Mené sur 90 patients atteints d'une leucémie lymphocytaire chronique ou d'un lymphome récidivant ou réfractaire, cet essai de phase I évalue la dose maximale tolérée et la toxicité de l'umbralisib, un inhibiteur nouvelle génération de PI3K delta, après l'échec d'une ou de plusieurs lignes thérapeutiques
During the past 5 years, the treatment landscape for patients with B-cell malignancies has seen a sharp increase in the array of available small molecules that target dysregulated pathways necessary for the survival and proliferation of the malignant clone.1 The phosphatidylinositol-3-kinase (PI3K) pathway has an important role in many cellular functions, including B-cell antigen receptor signalling. Selective inhibition of PI3K isoform
δ-dependent signalling has direct antitumour activity and exerts pleiotropic effects in the tumour microenvironment of B-cell malignancies, inducing apoptosis and reducing proliferation.
The Lancet Oncology , commentaire, 2017